Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
voriconazole, Quantity: 200 mg
Arrotex Pharmaceuticals Pty Ltd
Voriconazole
Tablet, film coated
Excipient Ingredients: lactose monohydrate; pregelatinised maize starch; maize starch; croscarmellose sodium; povidone; silicon dioxide; magnesium stearate; titanium dioxide; hypromellose; triacetin
Oral
2, 10, 14, 20, 28, 30, 50, 56, 100
(S4) Prescription Only Medicine
Voriconazole is indicated for treatment of the following fungal infections:Invasive aspergillosis. Serious Candida infections (including C. krusei), including oesophageal and systemic Candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). Serious fungal infections caused by Scedosporium spp and Fusarium spp. Other serious fungal infections, in patients intolerant of, or refractory to, other therapy. Prophylaxis in patients who are at high risk of developing invasive fungal infections. The indication is based on studies including patients undergoing haematopoietic stem cell transplantation.
Visual Identification: White, caplet shaped film coated 15.6 mm tablet with V200 debossed on one side and plain on other side.; Container Type: Blister Pack; Container Material: PVC/Al; Container Life Time: 3 Years; Container Temperature: Store below 30 degrees Celsius; Container Closure: Child resistant closure
Licence status A
2016-07-22